These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23726662)

  • 1. Population pharmacokinetic analysis of blood concentrations of robenacoxib in dogs with osteoarthritis.
    Fink M; Letellier I; Peyrou M; Mochel JP; Jung M; King JN; Gruet P; Giraudel JM
    Res Vet Sci; 2013 Oct; 95(2):580-7. PubMed ID: 23726662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial.
    Reymond N; Speranza C; Gruet P; Seewald W; King JN
    J Vet Pharmacol Ther; 2012 Apr; 35(2):175-83. PubMed ID: 21480932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety evaluation of the interchangeable use of robenacoxib (Onsior™) tablets and solution for injection in dogs.
    Toutain CE; Heit MC; King SB; Helbig R
    BMC Vet Res; 2017 Nov; 13(1):359. PubMed ID: 29179750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic analysis of blood and joint synovial fluid concentrations of robenacoxib from healthy dogs and dogs with osteoarthritis.
    Silber HE; Burgener C; Letellier IM; Peyrou M; Jung M; King JN; Gruet P; Giraudel JM
    Pharm Res; 2010 Dec; 27(12):2633-45. PubMed ID: 20922466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of route of administration and feeding schedule on pharmacokinetics of robenacoxib in cats.
    King JN; Jung M; Maurer MP; Schmid VB; Seewald W; Lees P
    Am J Vet Res; 2013 Mar; 74(3):465-72. PubMed ID: 23438125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analgesic and anti-inflammatory actions of robenacoxib in acute joint inflammation in dog.
    Schmid VB; Spreng DE; Seewald W; Jung M; Lees P; King JN
    J Vet Pharmacol Ther; 2010 Apr; 33(2):118-31. PubMed ID: 20444036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic/pharmacodynamic modelling of robenacoxib in a feline tissue cage model of inflammation.
    Pelligand L; King JN; Toutain PL; Elliott J; Lees P
    J Vet Pharmacol Ther; 2012 Feb; 35(1):19-32. PubMed ID: 21767277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the dose-response relationship of oral robenacoxib in urate crystal-induced acute stifle synovitis in dogs.
    Borer LR; Seewald W; Peel JE; King JN
    J Vet Pharmacol Ther; 2017 Apr; 40(2):148-157. PubMed ID: 27493016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential pharmacokinetics and pharmacokinetic/pharmacodynamic modelling of robenacoxib and ketoprofen in a feline model of inflammation.
    Pelligand L; King JN; Hormazabal V; Toutain PL; Elliott J; Lees P
    J Vet Pharmacol Ther; 2014 Aug; 37(4):354-66. PubMed ID: 24628410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of oral robenacoxib in the cat.
    King JN; Hotz R; Reagan EL; Roth DR; Seewald W; Lees P
    J Vet Pharmacol Ther; 2012 Jun; 35(3):290-300. PubMed ID: 21736587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.
    King JN; Dawson J; Esser RE; Fujimoto R; Kimble EF; Maniara W; Marshall PJ; O'Byrne L; Quadros E; Toutain PL; Lees P
    J Vet Pharmacol Ther; 2009 Feb; 32(1):1-17. PubMed ID: 19161451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of mavacoxib in osteoarthritic dogs.
    Cox SR; Liao S; Payne-Johnson M; Zielinski RJ; Stegemann MR
    J Vet Pharmacol Ther; 2011 Feb; 34(1):1-11. PubMed ID: 21219337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Robenacoxib in the dog: target species safety in relation to extent and duration of inhibition of COX-1 and COX-2.
    King JN; Arnaud JP; Goldenthal EI; Gruet P; Jung M; Seewald W; Lees P
    J Vet Pharmacol Ther; 2011 Jun; 34(3):298-311. PubMed ID: 21492194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety evaluation of the interchangeable use of robenacoxib in commercially-available tablets and solution for injection in cats.
    Heit MC; Stallons LJ; Seewald W; Thompson CM; Toutain CE; King SB; Helbig R
    BMC Vet Res; 2020 Sep; 16(1):355. PubMed ID: 32988403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Six-month safety evaluation of robenacoxib tablets (Onsior™) in dogs after daily oral administrations.
    Toutain CE; Brossard P; King SB; Helbig R
    BMC Vet Res; 2018 Aug; 14(1):242. PubMed ID: 30119677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib.
    Lees P; Toutain PL; Elliott J; Giraudel JM; Pelligand L; King JN
    J Vet Pharmacol Ther; 2022 Jul; 45(4):325-351. PubMed ID: 35460083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of robenacoxib on the concentration of C-reactive protein in synovial fluid from dogs with osteoarthritis.
    Bennett D; Eckersall PD; Waterston M; Marchetti V; Rota A; McCulloch E; Sbrana S
    BMC Vet Res; 2013 Mar; 9():42. PubMed ID: 23452411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of oral robenacoxib and carprofen for the treatment of osteoarthritis in dogs: a randomized clinical trial.
    Edamura K; King JN; Seewald W; Sakakibara N; Okumura M
    J Vet Med Sci; 2012 Sep; 74(9):1121-31. PubMed ID: 22673598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can liquorice extract and herbal solution prevent colonic mucosa damage caused by robenacoxib in dogs?
    Szweda M; Szarek J; Lew M; Szarek-Bęska A; Gulda D
    Pol J Vet Sci; 2015; 18(4):793-8. PubMed ID: 26812822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analytical determination and pharmacokinetics of robenacoxib in the dog.
    Jung M; Lees P; Seewald W; King JN
    J Vet Pharmacol Ther; 2009 Feb; 32(1):41-8. PubMed ID: 19161454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.